3-(2-bromopyridin-3-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(2-bromopyridin-3-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide
• 化学式: C₁₇H₁₄BrN₃O
• 分子量: 356.2
• InChiKey: OZLFNWBBDHKOPZ-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  65.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Orally Bioavailable Caffeic Acid Related Anticancer Drugs
  申请人：Priebe Waldemar

  公开号：US20070232668A1

  公开（公告）日：2007-10-04

  The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.

  本发明涉及化合物及其用于治疗细胞增殖性疾病如癌症的用途。本发明的化合物作为Jak2/STAT3途径和下游靶点的抑制剂显示出显著的效力，并抑制癌细胞系的生长和存活。
• ORALLY BIOAVAILABLE CAFFEIC ACID RELATED ANTICANCER DRUGS
  申请人：The Board of Regents of the University of Texas System

  公开号：US20150094343A1

  公开（公告）日：2015-04-02

  The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.

  本发明涉及化合物及其用于治疗细胞增殖性疾病，例如癌症。本发明的化合物作为Jak2 / STAT3途径及下游靶点的抑制剂具有显著的效力，并抑制癌细胞系的生长和存活。
• Orally bioavailable cafeic acid related anticancer drugs
  申请人：The Board of Regents of The University of Texas System

  公开号：EP2514742A2

  公开（公告）日：2012-10-24

  The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.

  本发明涉及化合物及其用于治疗癌症等细胞增殖性疾病。本发明的化合物作为 Jak2/STAT3 通路和下游靶点的抑制剂具有显著的效力，可抑制癌细胞株的生长和存活。
• METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS
  申请人：Priebe Anna

  公开号：US20110275577A1

  公开（公告）日：2011-11-10

  The present invention relates to caffeic acid analog compounds and methods which may be useful for regeneration, cellular programming, and the treatment of dermatologic, gynecologic, and genital diseases such as inflammatory dermatologic conditions, dysplasia, neoplasia, in situ carcinoma, invasive carcinoma, lichen sclerosus, lichen planus, vaginal dysplasia, vaginal carcinoma, vulvar dysplasia, vulvar carcinoma, cervical dysplasia, cervical carcinoma, and Kaposi's sarcoma.
• INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION
  申请人：Priebe Waldemar

  公开号：US20130129675A1

  公开（公告）日：2013-05-23

  Methods of modulating the INF-induced STAT3 activation in a patient in need-thereof are provided for the treatment of disease. The methods comprise the step of administrating to a patient the combination of a therapeutically effective amount of interferon including INF-α and/or INF-β in combination with a STAT3 inhibitor.